<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02190097</url>
  </required_header>
  <id_info>
    <org_study_id>14-13770</org_study_id>
    <nct_id>NCT02190097</nct_id>
  </id_info>
  <brief_title>Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)</brief_title>
  <official_title>PALEOLITHIC VS Healthy ADA DIETS FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a syndrome which includes elevated androgen levels,&#xD;
      irregular menstrual cycles and insulin resistance. Standard treatments, which include weight&#xD;
      loss and medications to improve insulin secretion are only partly successful, and may require&#xD;
      that young women take medications for decades.&#xD;
&#xD;
      The study investigators have been evaluating the effects of specific diets on insulin&#xD;
      resistance in healthy volunteers and subjects with type 2 diabetes, and have found that&#xD;
      subjects with insulin resistance seem to respond particularly well to these diet regimens.&#xD;
&#xD;
      Volunteers with PCOS are being asked to participate to see if following these diets can help&#xD;
      regularize your menstrual cycles. The results of this study may help improve fertility&#xD;
      treatments for women with PCOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental Design and Methods This is a prospective, open labeled, randomized diet&#xD;
      intervention study done on adult participants with PCOS. After signing informed consents,&#xD;
      participants will be asked to eat a recommended ADA diet for two weeks (run in period).&#xD;
      Participants will then have baseline testing, including: urine and blood tests to evaluate&#xD;
      insulin resistance (fasting glucose and insulin, 2 hour oral glucose tolerance test),&#xD;
      electrolytes to assess acid-base status, ovarian volume and testosterone levels measured to&#xD;
      assess severity of PCOS, and questionnaires about menstrual frequency, eating habits and&#xD;
      stress. Participants will then be randomized to either a high fruits and vegetable Paleo Diet&#xD;
      for 4-8 months or a standard ADA-recommended diet for the first 4 months followed by Paleo&#xD;
      Diet for 0-4 months.All participants will have the option of limiting their participation to&#xD;
      just 4 months or extending participation to the full 8 months depending on their ongoing&#xD;
      level of interest. All testing will be repeated at 4 months (crossover point) and at&#xD;
      completion of the diets at 8 months. The primary outcome variables are menstrual cycle&#xD;
      frequency and ovarian volume, and secondary outcomes include metabolic profiles and&#xD;
      eating/behavior questionnaires&#xD;
&#xD;
      Procedures&#xD;
&#xD;
        1. Diet: All participants will initially be given diet information on ADA diet for the &quot;Run&#xD;
           In&quot; period , including printed ADA diet instructions and advice on caloric intake. The&#xD;
           ADA diet includes foods that are excluded in the Paleo Diet, such as grains, legumes and&#xD;
           dairy products and will also contain less potassium. All participants will be instructed&#xD;
           not to add salt to their food when cooking or eating. At 2 weeks, participants will be&#xD;
           randomized to Paleo Diet arm or ADA diet arm. Participants on the Paleo Diet arm will&#xD;
           require a &quot;ramp-up&quot; phase for one week (start out with 1 Paleo meal per day, then two,&#xD;
           and then all meals will be on a Paleolithic-type menu, which contains approximately an&#xD;
           average of 142 grams of protein and 12,200 mg of potassium per 3000 kcal. Participants&#xD;
           on the ADA diet arm will continue on the run-in diet.&#xD;
&#xD;
           After 16 weeks, the participants in the ADA arm will be changed over to the Paleo arm if&#xD;
           they wish to continue participation. They will also require a &quot;ramp-up&quot; phase for 1&#xD;
           week. In our previous studies, we have seen a crossover effect at one month going from&#xD;
           the Paleo to the ADA diet, but not from the ADA to the Paleo arm.&#xD;
&#xD;
           We will give all participants pertinent websites and written information about their&#xD;
           specific diet, as well as sample menus. We will give participants in the Paleo arm a&#xD;
           list of foods to avoid (e.g., dairy, grains, legumes, processed foods).&#xD;
&#xD;
           The main obstacles to compliance with outpatient diets include the cost, the amount of&#xD;
           time needed, and ignorance about where to get specific kinds of foods. We will give them&#xD;
           lists of various supermarkets and farmers markets times and dates, we will advise&#xD;
           participants about making up batches of foods on the weekends and freezing them, and if&#xD;
           they have families or other support, we will try to get them involved in support.&#xD;
&#xD;
        2. Monitoring dietary compliance: We will monitor compliance in a number of ways.&#xD;
&#xD;
      We have recruited four nutrition student volunteers from UC Berkeley, who will work closely&#xD;
      with the participants to help them adapt the study diets to their everyday living situations.&#xD;
      The nutrition students will help design the materials we will give the participants, as well&#xD;
      as give dietary advice. We are working on a number of electronic and social media methods for&#xD;
      keeping track of what our subjects are eating. These include:&#xD;
&#xD;
        -  Initially daily, or near daily contacts for the first week of each diet, then at least&#xD;
           weekly contacts, and then at least monthly contacts.&#xD;
&#xD;
        -  online data system that monitors food and activity (e.g., the USDA super tracker,&#xD;
           myfitnesspal, etc).&#xD;
&#xD;
        -  tweets or texts that ask the subjects to go to an elink and answer a few questions,&#xD;
           e.g., did you eat grains today? The answers are downloaded to a database that can be&#xD;
           compiled to reflect dietary compliance for each subject.&#xD;
&#xD;
      We will also develop a secure website so that participants from each group can discuss with&#xD;
      others what problems and solutions they are using.&#xD;
&#xD;
      Last, we will also assess 24 hour urines for creatinine, sodium, and potassium at 0, 16 and&#xD;
      32 weeks. Both of these diets will be higher in potassium and lower in sodium than typical&#xD;
      American diets. Although we expect our subjects will be motivated enough to follow these&#xD;
      diets, from our previous studies we have found that some subjects were not honest about what&#xD;
      they were eating, and this was reflected in the 24 hour urine excretion of potassium and&#xD;
      sodium.&#xD;
&#xD;
      Assays:&#xD;
&#xD;
      Samples will be drawn at time 0; week 8; week 16; week 24 and week 32. We will collect serum,&#xD;
      plasma and urine at all these timepoints for banking. The following tests will be performed&#xD;
      at time (table 2):&#xD;
&#xD;
        1. CBC, Chemical profile; blood lipids; cardiovascular risk factors and inflammatory&#xD;
           cytokines and adipokines (time 0, week 16, week 32): Electrolytes, liver function tests,&#xD;
           fasting glucose, lipid panel and insulin levels will be measured by Quest labs. PAI-1&#xD;
           will be measured by a colorimetric assay (Chemicon, Temecula, CA). Homocysteine,&#xD;
           fibrinogen, hsCRP and ICAM-1 will be assayed by the UCSF clinical laboratory using&#xD;
           standard analytical methods. Commercial kits will be used to measure fasting serum&#xD;
           non-esterified fatty acids (Wako Diagnostics kit ;Richmond Virginia); serum TNF-α ,&#xD;
           IL-6, adiponectin and leptin (Quantikine HS high sensitivity ELISA ;R &amp; D Systems,&#xD;
           Minneapolis, MN&#xD;
&#xD;
        2. Systemic oxidative stress (time 0, weeks 16, 32): we will measure 4 serum markers of&#xD;
           oxidative stress; protein carbonyls (a product of protein oxidation), TBARS (a&#xD;
           measurement of lipid peroxidation), TRAP (a measure of total antioxidant activity), and&#xD;
           isoprostanes (formed from the peroxidation of arachidonic acid in lipoproteins and&#xD;
           membranes). Blood samples will be drawn in the fasted state both at initial screening&#xD;
           and after ALA treatment. Protein carbonyls, TBARS, and TRAP will be performed at UC&#xD;
           Davis Clinical Laboratories employing standard techniques. Serum 8-isoprostane-F2α will&#xD;
           be measured by KRONOS Science laboratory, Phoenix Arizona. We will also measure urine&#xD;
           markers of oxidative stress before and after CRLA treatment. These will include&#xD;
           8-isoprostane-F2α, and 8-hydroxy guanosine (a marker of oxidized DNA). These urine&#xD;
           assays will be performed KRONOS Science laboratory, Phoenix Arizona and Dr Jack Roberts,&#xD;
           Vanderbilt University.&#xD;
&#xD;
        3. Telomere assessment. The length of telomeres, the DNA caps at the ends of chromosomes,&#xD;
           is emerging as an indicator of stress-related biological aging: Data have implicated&#xD;
           accelerated telomere shortening in the context of increased psychological stress and&#xD;
           stress arousal [10, 11]Blood drawn by a licensed phlebotomist (4 mL for telomere&#xD;
           assessment) at baseline (0 weeks) and 16-weeks will be assayed for telomere length.&#xD;
           Samples will be frozen and transferred on dry ice to the Blackburn Laboratory at UCSF,&#xD;
           located at 600 16th Street, San Francisco, California, by a laboratory technician.&#xD;
           Assays will be completed according to the polymerase chain reaction (PCR) method..&#xD;
&#xD;
        4. 24 hr urine collections . collections as per clinical protocol. We will measure volume,&#xD;
           Na, K, pH, creatinine and calcium&#xD;
&#xD;
           Reproductive testing:&#xD;
&#xD;
           Subjects will undergo assessment of 1)SHBG and androgen levels: total testosterone,&#xD;
           androstenedione and DHEAS; 2) clinical hyperandrogenism: hirsutism by modified&#xD;
           Ferriman-Gallwey and acne scores; 3) menstrual cyclicity (cycle interval and pattern);&#xD;
           and 4) ovarian morphology (follicle count and ovarian volume).&#xD;
&#xD;
           Androgen levels (times 0, weeks 16, 32): Two serum samples will be obtained 30 minutes&#xD;
           apart.. Serum will be isolated and aliquoted for future analysis of androstenedione (A),&#xD;
           testosterone (T), DHEAS, 17 hydroxyprogesterone (17-OHP) and SHBG.&#xD;
&#xD;
           Clinical hyperandrogenism: The presence and extent of hirsutism will be determined using&#xD;
           a modification of the Ferriman-Gallwey (FG) scoring method[12] while acne will be scored&#xD;
           according to the American Academy of Dermatology .Subjects will be requested to avoid&#xD;
           any mechanical treatment for hair removal for 4 weeks prior to the baseline visit and to&#xD;
           list all such treatments that are utilized during the study and their frequency.&#xD;
&#xD;
           Menstrual cyclicity: Menstrual frequency will be assessed as a menstrual frequency ratio&#xD;
           as described by Elkind-Hirsch [13]so that menstrual events are normalized to the normal&#xD;
           interval of 12 menses per year (MFR=1.0) or, for instance, those with 6 cycles per year&#xD;
           would have an MFR of 0.5.&#xD;
&#xD;
           Ovarian morphology: All subjects will undergo a transvaginal ultrasound (TVUS) to obtain&#xD;
           an antral follicle count at baseline, 8 and 16 weeks. The study investigator will image&#xD;
           both the left and right adnexal areas in two planes, and make measurements of the&#xD;
           transverse, longitudinal, and anteroposterior diameters of each ovary using electronic&#xD;
           calipers on a Shimadzu SDU-450XL machine with a variable 4-8 mHz vaginal transducer. The&#xD;
           examination of each adnexa will ensure an adequate opportunity to locate the organs.&#xD;
           Inability to locate adnexa in this age group is less than 1% (internal data). All&#xD;
           echo-free structures in the ovaries will be regarded as follicles. Follicles with a mean&#xD;
           diameter (of two dimensions) between 2 and 10 mm will be counted. Calculation of all&#xD;
           follicles (2-10mm), as well as those 2- 5mm, will be possible as these numbers will be&#xD;
           recorded separately. The total between the two ovaries (2- 10mm) will be considered the&#xD;
           AFC. The volume of each ovary will be calculated by measuring the three perpendicular&#xD;
           diameters and applying the formula for an ellipsoid: (L x H x W x π/6). Data will be&#xD;
           entered directly onto scannable datasheets. Examination will also determine whether&#xD;
           cysts/other abnormalities exist and provide images to document number and type of&#xD;
           abnormalities. Clinical alerts will be generated for ovarian cysts of greater than 3cm&#xD;
           diameter or solid adnexal masses of any size. Dr. Huddleston will be responsible for&#xD;
           relaying information about clinical alerts to patients and physicians.&#xD;
&#xD;
        5. Body composition: Total body water (TBW) and extracellular water (ECW) volumes will be&#xD;
           determined by bioimpedance spectroscopy (Intermed Inc, Melbourne Australia) at baseline,&#xD;
           16 and 32 weeks. Subjects will also be weighed at each visit. We will also do waist and&#xD;
           hip measurements at baseline, 16 and 32 weeks .&#xD;
&#xD;
        6. Blood pressure (BP) and heart rate (HR): These will be measured at each visit in the&#xD;
           morning after 10 minutes of rest in the sitting position using an automated&#xD;
           oscillometric device (Dinamap, Critikon Inc) programmed to obtain 3 readings within 3&#xD;
           minutes, and then will calculate average daily pressure&#xD;
&#xD;
      j. Questionnaires: Participants will complete the following questionnaires per the schedule&#xD;
      specified in Table 1. Questionnaires tap psychological experience, health and eating&#xD;
      behavior, and adherence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">August 29, 2022</completion_date>
  <primary_completion_date type="Actual">July 29, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>menstrual cycle frequency</measure>
    <time_frame>4 months</time_frame>
    <description>questionnaires, ovarian ultrasound for volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>4 months</time_frame>
    <description>fasting glucose and insulin, 2 hour oral glucose tolerance tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <arm_group>
    <arm_group_label>paleolithic diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>American Diabetes Association diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Paleolithic diet</intervention_name>
    <description>see procedures section for more details</description>
    <arm_group_label>paleolithic diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>American Diabetes Association diet</intervention_name>
    <description>see procedures section</description>
    <arm_group_label>American Diabetes Association diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion in the study is restricted to reproductive age women with PCOS&#xD;
&#xD;
          -  Chronic oligo/anovulation defined as an intermenstrual interval of &gt;45 days and/or &lt; 8&#xD;
             menstrual cycles/year and evidence of either hyperandrogenemia (elevation of total or&#xD;
             free testosterone above the normal range for women) and/or clinical hyperandrogenism&#xD;
             (hirsutism and/or acne)&#xD;
&#xD;
          -  Age 18-40&#xD;
&#xD;
          -  Agreeable to avoidance of pregnancy and to use barrier contraception for duration of&#xD;
             study&#xD;
&#xD;
          -  BMI between 18 to 40 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other abnormalities which might lead to anovulation: hyperprolactinemia, thyroid&#xD;
             dysfunction and other causes of hyperandrogenemia including late onset congenital&#xD;
             hyperplasia&#xD;
&#xD;
          -  Evidence of diabetes based on a fasting glucose &gt;126 mg/dl or OGTT&#xD;
&#xD;
          -  Use of medications and/or supplements that influence either ovarian function or&#xD;
             insulin sensitivity, within 2 months: including oral contraceptive pills, hormonal&#xD;
             implants, anti-androgens, antipsychotics or antihypertensives metformin,&#xD;
             glucocorticoids, and/or health food remedies other than multi-vitamins and calcium;&#xD;
&#xD;
          -  Subjects who are on oral contraception, metformin, or nutritional supplements must&#xD;
             agree to discontinue these drugs and undergo an 8 week washout period before the tests&#xD;
             are performed&#xD;
&#xD;
          -  Alcohol usage more than 7 drinks/week&#xD;
&#xD;
          -  Hemoglobin &lt; 10 grams&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Inability to understand the study goals and protocols and the consent form&#xD;
&#xD;
          -  Any subject, who in the opinion of the investigators, does not qualify for the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Huddleston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>November 30, 2022</last_update_submitted>
  <last_update_submitted_qc>November 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>paleolithic diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>would share only with participant, if asked by participant</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02190097/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02190097
org study id: 14-13770
nct id: NCT02190097
lead sponsor: 
has dmc: No
Polycystic ovary syndrome (PCOS) is a syndrome which includes elevated androgen levels,
      irregular menstrual cycles and insulin resistance. Standard treatments, which include weight
      loss and medications to improve insulin secretion are only partly successful, and may require
      that young women take medications for decades.

      The study investigators have been evaluating the effects of specific diets on insulin
      resistance in healthy volunteers and subjects with type 2 diabetes, and have found that
      subjects with insulin resistance seem to respond particularly well to these diet regimens.

      Volunteers with PCOS are being asked to participate to see if following these diets can help
      regularize your menstrual cycles. The results of this study may help improve fertility
      treatments for women with PCOS.
Experimental Design and Methods This is a prospective, open labeled, randomized diet
      intervention study done on adult participants with PCOS. After signing informed consents,
      participants will be asked to eat a recommended ADA diet for two weeks (run in period).
      Participants will then have baseline testing, including: urine and blood tests to evaluate
      insulin resistance (fasting glucose and insulin, 2 hour oral glucose tolerance test),
      electrolytes to assess acid-base status, ovarian volume and testosterone levels measured to
      assess severity of PCOS, and questionnaires about menstrual frequency, eating habits and
      stress. Participants will then be randomized to either a high fruits and vegetable Paleo Diet
      for 4-8 months or a standard ADA-recommended diet for the first 4 months followed by Paleo
      Diet for 0-4 months.All participants will have the option of limiting their participation to
      just 4 months or extending participation to the full 8 months depending on their ongoing
      level of interest. All testing will be repeated at 4 months (crossover point) and at
      completion of the diets at 8 months. The primary outcome variables are menstrual cycle
      frequency and ovarian volume, and secondary outcomes include metabolic profiles and
      eating/behavior questionnaires

      Procedures

        1. Diet: All participants will initially be given diet information on ADA diet for the "Run
           In" period , including printed ADA diet instructions and advice on caloric intake. The
           ADA diet includes foods that are excluded in the Paleo Diet, such as grains, legumes and
           dairy products and will also contain less potassium. All participants will be instructed
           not to add salt to their food when cooking or eating. At 2 weeks, participants will be
           randomized to Paleo Diet arm or ADA diet arm. Participants on the Paleo Diet arm will
           require a "ramp-up" phase for one week (start out with 1 Paleo meal per day, then two,
           and then all meals will be on a Paleolithic-type menu, which contains approximately an
           average of 142 grams of protein and 12,200 mg of potassium per 3000 kcal. Participants
           on the ADA diet arm will continue on the run-in diet.

           After 16 weeks, the participants in the ADA arm will be changed over to the Paleo arm if
           they wish to continue participation. They will also require a "ramp-up" phase for 1
           week. In our previous studies, we have seen a crossover effect at one month going from
           the Paleo to the ADA diet, but not from the ADA to the Paleo arm.

           We will give all participants pertinent websites and written information about their
           specific diet, as well as sample menus. We will give participants in the Paleo arm a
           list of foods to avoid (e.g., dairy, grains, legumes, processed foods).

           The main obstacles to compliance with outpatient diets include the cost, the amount of
           time needed, and ignorance about where to get specific kinds of foods. We will give them
           lists of various supermarkets and farmers markets times and dates, we will advise
           participants about making up batches of foods on the weekends and freezing them, and if
           they have families or other support, we will try to get them involved in support.

        2. Monitoring dietary compliance: We will monitor compliance in a number of ways.

      We have recruited four nutrition student volunteers from UC Berkeley, who will work closely
      with the participants to help them adapt the study diets to their everyday living situations.
      The nutrition students will help design the materials we will give the participants, as well
      as give dietary advice. We are working on a number of electronic and social media methods for
      keeping track of what our subjects are eating. These include:

        -  Initially daily, or near daily contacts for the first week of each diet, then at least
           weekly contacts, and then at least monthly contacts.

        -  online data system that monitors food and activity (e.g., the USDA super tracker,
           myfitnesspal, etc).

        -  tweets or texts that ask the subjects to go to an elink and answer a few questions,
           e.g., did you eat grains today? The answers are downloaded to a database that can be
           compiled to reflect dietary compliance for each subject.

      We will also develop a secure website so that participants from each group can discuss with
      others what problems and solutions they are using.

      Last, we will also assess 24 hour urines for creatinine, sodium, and potassium at 0, 16 and
      32 weeks. Both of these diets will be higher in potassium and lower in sodium than typical
      American diets. Although we expect our subjects will be motivated enough to follow these
      diets, from our previous studies we have found that some subjects were not honest about what
      they were eating, and this was reflected in the 24 hour urine excretion of potassium and
      sodium.

      Assays:

      Samples will be drawn at time 0; week 8; week 16; week 24 and week 32. We will collect serum,
      plasma and urine at all these timepoints for banking. The following tests will be performed
      at time (table 2):

        1. CBC, Chemical profile; blood lipids; cardiovascular risk factors and inflammatory
           cytokines and adipokines (time 0, week 16, week 32): Electrolytes, liver function tests,
           fasting glucose, lipid panel and insulin levels will be measured by Quest labs. PAI-1
           will be measured by a colorimetric assay (Chemicon, Temecula, CA). Homocysteine,
           fibrinogen, hsCRP and ICAM-1 will be assayed by the UCSF clinical laboratory using
           standard analytical methods. Commercial kits will be used to measure fasting serum
           non-esterified fatty acids (Wako Diagnostics kit ;Richmond Virginia); serum TNF-α ,
           IL-6, adiponectin and leptin (Quantikine HS high sensitivity ELISA ;R & D Systems,
           Minneapolis, MN

        2. Systemic oxidative stress (time 0, weeks 16, 32): we will measure 4 serum markers of
           oxidative stress; protein carbonyls (a product of protein oxidation), TBARS (a
           measurement of lipid peroxidation), TRAP (a measure of total antioxidant activity), and
           isoprostanes (formed from the peroxidation of arachidonic acid in lipoproteins and
           membranes). Blood samples will be drawn in the fasted state both at initial screening
           and after ALA treatment. Protein carbonyls, TBARS, and TRAP will be performed at UC
           Davis Clinical Laboratories employing standard techniques. Serum 8-isoprostane-F2α will
           be measured by KRONOS Science laboratory, Phoenix Arizona. We will also measure urine
           markers of oxidative stress before and after CRLA treatment. These will include
           8-isoprostane-F2α, and 8-hydroxy guanosine (a marker of oxidized DNA). These urine
           assays will be performed KRONOS Science laboratory, Phoenix Arizona and Dr Jack Roberts,
           Vanderbilt University.

        3. Telomere assessment. The length of telomeres, the DNA caps at the ends of chromosomes,
           is emerging as an indicator of stress-related biological aging: Data have implicated
           accelerated telomere shortening in the context of increased psychological stress and
           stress arousal [10, 11]Blood drawn by a licensed phlebotomist (4 mL for telomere
           assessment) at baseline (0 weeks) and 16-weeks will be assayed for telomere length.
           Samples will be frozen and transferred on dry ice to the Blackburn Laboratory at UCSF,
           located at 600 16th Street, San Francisco, California, by a laboratory technician.
           Assays will be completed according to the polymerase chain reaction (PCR) method..

        4. 24 hr urine collections . collections as per clinical protocol. We will measure volume,
           Na, K, pH, creatinine and calcium

           Reproductive testing:

           Subjects will undergo assessment of 1)SHBG and androgen levels: total testosterone,
           androstenedione and DHEAS; 2) clinical hyperandrogenism: hirsutism by modified
           Ferriman-Gallwey and acne scores; 3) menstrual cyclicity (cycle interval and pattern);
           and 4) ovarian morphology (follicle count and ovarian volume).

           Androgen levels (times 0, weeks 16, 32): Two serum samples will be obtained 30 minutes
           apart.. Serum will be isolated and aliquoted for future analysis of androstenedione (A),
           testosterone (T), DHEAS, 17 hydroxyprogesterone (17-OHP) and SHBG.

           Clinical hyperandrogenism: The presence and extent of hirsutism will be determined using
           a modification of the Ferriman-Gallwey (FG) scoring method[12] while acne will be scored
           according to the American Academy of Dermatology .Subjects will be requested to avoid
           any mechanical treatment for hair removal for 4 weeks prior to the baseline visit and to
           list all such treatments that are utilized during the study and their frequency.

           Menstrual cyclicity: Menstrual frequency will be assessed as a menstrual frequency ratio
           as described by Elkind-Hirsch [13]so that menstrual events are normalized to the normal
           interval of 12 menses per year (MFR=1.0) or, for instance, those with 6 cycles per year
           would have an MFR of 0.5.

           Ovarian morphology: All subjects will undergo a transvaginal ultrasound (TVUS) to obtain
           an antral follicle count at baseline, 8 and 16 weeks. The study investigator will image
           both the left and right adnexal areas in two planes, and make measurements of the
           transverse, longitudinal, and anteroposterior diameters of each ovary using electronic
           calipers on a Shimadzu SDU-450XL machine with a variable 4-8 mHz vaginal transducer. The
           examination of each adnexa will ensure an adequate opportunity to locate the organs.
           Inability to locate adnexa in this age group is less than 1% (internal data). All
           echo-free structures in the ovaries will be regarded as follicles. Follicles with a mean
           diameter (of two dimensions) between 2 and 10 mm will be counted. Calculation of all
           follicles (2-10mm), as well as those 2- 5mm, will be possible as these numbers will be
           recorded separately. The total between the two ovaries (2- 10mm) will be considered the
           AFC. The volume of each ovary will be calculated by measuring the three perpendicular
           diameters and applying the formula for an ellipsoid: (L x H x W x π/6). Data will be
           entered directly onto scannable datasheets. Examination will also determine whether
           cysts/other abnormalities exist and provide images to document number and type of
           abnormalities. Clinical alerts will be generated for ovarian cysts of greater than 3cm
           diameter or solid adnexal masses of any size. Dr. Huddleston will be responsible for
           relaying information about clinical alerts to patients and physicians.

        5. Body composition: Total body water (TBW) and extracellular water (ECW) volumes will be
           determined by bioimpedance spectroscopy (Intermed Inc, Melbourne Australia) at baseline,
           16 and 32 weeks. Subjects will also be weighed at each visit. We will also do waist and
           hip measurements at baseline, 16 and 32 weeks .

        6. Blood pressure (BP) and heart rate (HR): These will be measured at each visit in the
           morning after 10 minutes of rest in the sitting position using an automated
           oscillometric device (Dinamap, Critikon Inc) programmed to obtain 3 readings within 3
           minutes, and then will calculate average daily pressure

      j. Questionnaires: Participants will complete the following questionnaires per the schedule
      specified in Table 1. Questionnaires tap psychological experience, health and eating
      behavior, and adherence.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: menstrual cycle frequency
time frame: 4 months
description: questionnaires, ovarian ultrasound for volume
measure: insulin sensitivity
time frame: 4 months
description: fasting glucose and insulin, 2 hour oral glucose tolerance tests
arm group label: paleolithic diet
arm group type: Experimental
description: subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
arm group label: American Diabetes Association diet
arm group type: Active Comparator
description: subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
intervention type: Other
intervention name: Paleolithic diet
description: see procedures section for more details
arm group label: paleolithic diet
intervention type: Other
intervention name: American Diabetes Association diet
description: see procedures section
arm group label: American Diabetes Association diet
criteria: 
gender: Female
minimum age: 18 Years
maximum age: 40 Years
healthy volunteers: No
last name: Heather Huddleston, MD
role: Principal Investigator
affiliation: University of California, San Francisco
facility: 
country: United States
responsible party type: Sponsor
mesh term: Polycystic Ovary Syndrome
mesh term: Syndrome
sharing ipd: No
ipd description: would share only with participant, if asked by participant
provided document: 